Description
Name | glyburide |
Appearance | White crystalline powder |
Cas | 10238-21-8 |
MF | C23H22ClN3O5S |
Mol. mass | 487.9559 |
Grade | Medicine grade |
Assay | 99.6% |
Density | 1.376g/cm3 |
EINECS | 233-570-6 |
Usage | Hypoglycemic |
Delivery | 1 to 3 days |
Package | 1kg/Aluminum foil bag,25kg/drum |
Medical uses
Glybenzcyclamide (INN), also known as glyburide (USAN), a second-generation sulfonylurea antidiabetic agent, appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonyl-urea hypoglycemic drugs. The combination of glibenclamide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. In addition to its blood glucose lowering actions, glibenclamide produces a mild diuresis by enhancement of renal free water clearance. Glybenzcyclamide is twice as potent as the related second-generation agent glipizide.
Contact informationGary Ren
Zhengzhou Debao Fine Chemical co., ltd
Phone: 86 150 3800 2977
Tel: 86 371 69123168
Glybenzcyclamide 10238-21-8